That is a thing (though arguably there is still value in the reformulations). A good current example would be orally administered wegovy, which received an addi

That is a thing (though arguably there is still value in the reformulations). A good current example would be orally administered wegovy, which received an additional patent on top of semaglutide for combining the drug with an absorption enhancer. This is a genuine advancement, and did require clinical trials (not all patentable improvements do) but it is ultimately just a variation on an existing drug. That being said, the patent on semaglutide still expires at the same time and biosimilars (or generics in other cases) can be produced at that time using the injectable formulation (or a new alternative). This seems reasonable to me